Try our Advanced Search for more refined results

In Re: National Prescription Opiate Litigation

Track this case

Case overview

Case Number:

1:17-md-02804

See also:

Court:

Ohio Northern

Nature of Suit:

P.I.: Other

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

Dan Aaron Polster (MDL 28

Firms

Companies

Government Agencies

Sectors & Industries:

  1. September 30, 2022

    Administrator Named In CVS-Walgreens-Walmart Opioid Order

    A Cleveland federal judge presiding over thousands of opioid cases appointed his special master on Friday as administrator for abatement programs mandated as part of a judgment against CVS, Walgreens and Walmart, which were found liable to the tune of $650 million for contributing to prescription painkiller-related problems in two Ohio counties.

  2. September 21, 2022

    Opioid MDL Attys To Get 'Much More Aggressive' As Talks Lag

    Months of talks with drug companies poised to become the next big targets in multidistrict opioid litigation haven't yielded major progress, and a "much more aggressive" approach is needed, one of the highest-ranking attorneys for MDL plaintiffs said Wednesday.

  3. September 07, 2022

    CVS, Walgreens, Walmart Will Fight $650M Ohio Opioid Order

    Three major pharmacy chains plan to challenge a federal judge's order to pay more than $650 million toward a plan to abate the opioid epidemic in two Northeast Ohio counties, according to notices of appeal filed Wednesday.

  4. September 06, 2022

    Pharmacies Flooded NM With Opioids, AG Says As Trial Starts

    New Mexico's attorney general launched an opioid-crisis trial on Tuesday against three pharmacy giants with a comparison of stewardship of drugs to that of water in his arid state, saying reckless opioid dispensing by Walgreens, Walmart and Kroger "smashed those dams wide open."

  5. September 02, 2022

    The Hottest Topics For Health Attys In 2022's Homestretch

    A torrid 2022 for health care litigation is entering a red-hot homestretch featuring fallout from the U.S. Supreme Court's explosive repudiation of abortion rights, the potential for three False Claims Act clashes at the high court, and the increasingly likely prospect of a funding fiasco for the U.S. Food and Drug Administration.

  6. August 18, 2022

    Lanier On $650M Opioid Win: I'd Have Settled For 'A Lot' Less

    Following a $650 million opioid trial triumph Wednesday against CVS Pharmacy, Walgreens and Walmart, lead plaintiffs counsel W. Mark Lanier told Law360 that the pharmacies "could have settled so much cheaper than this, it's not even funny," and that while the appeal process could take years, he's "not too panicked" about the chains' chances.

  7. August 17, 2022

    CVS, Walmart, Walgreens Owe $650M In Ohio Opioid Fallout

    A federal judge in Cleveland said Wednesday that three major pharmacy chains must pay more than $650 million to fund a 15-year plan to address the fallout from opioid abuse in two northeast Ohio counties, delivering a blow to pharmacy companies as more cases make their way to trial.

  8. August 11, 2022

    Winless In Opioid Bouts, Will Pharmacies Throw In The Towel?

    A California federal judge's walloping of Walgreens over its narcotic painkiller sales in San Francisco has left pharmacy chains 0 for 2 in opioid trials and is casting doubt on the companies' apparent plans to continue stepping into the legal ring with government adversaries.

  9. August 10, 2022

    Walgreens Fueled SF Opioid Epidemic, Judge Rules

    Pharmacy giant Walgreens dispensed hundreds of thousands of suspicious prescriptions for narcotic painkillers in San Francisco without proper screening and is liable for ensuing opioid problems in the Bay Area, a California federal judge ruled Wednesday.

  10. August 05, 2022

    Landmark Opioid Opinion 'Not Persuasive,' W.Va. Panel Says

    A West Virginia federal judge contravened long-standing precedent when he sided with drug distributors last month after a major opioid crisis trial, the Mountain State's Mass Litigation Panel said in a ruling against national pharmacy chains that are approaching a similar trial.